EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Rigel Pharmaceuticals, Inc. (RIGL) had EBIT Margin of 60.09% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$101.69M |
|
$59.61M |
|
$4.50M |
|
$97.18M |
|
$40.58M |
|
$61.10M |
|
$-1.12M |
|
$59.98M |
|
$59.98M |
|
$59.61M |
|
$59.61M |
|
$59.61M |
|
$59.61M |
|
$61.10M |
|
$61.46M |
|
17.89M |
|
18.16M |
|
$3.33 |
|
$3.28 |
|
| Balance Sheet Financials | |
$175.39M |
|
$0.06M |
|
$31.34M |
|
$206.74M |
|
$86.64M |
|
$37.45M |
|
$38.17M |
|
$124.80M |
|
$81.93M |
|
$56.01M |
|
$81.93M |
|
17.94M |
|
| Cash Flow Statement Financials | |
$29.64M |
|
$-33.83M |
|
$0.90M |
|
$56.75M |
|
$53.46M |
|
$-3.28M |
|
$6.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.02 |
|
-- |
|
-- |
|
0.31 |
|
0.73 |
|
95.57% |
|
60.09% |
|
|
EBIT Margin |
60.09% |
-- |
|
58.99% |
|
58.63% |
|
$29.64M |
|
-- |
|
-- |
|
-- |
|
0.49 |
|
0.43 |
|
2.55 |
|
35.32 |
|
72.76% |
|
106.43% |
|
28.84% |
|
49.93% |
|
$4.57 |
|
$1.63 |
|
$1.63 |
|